Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction

Year 2023, , 99 - 104, 31.01.2023

Sena Sert Emre Karabay Baris Gungor Ozlem Yıldırımturk

https://doi.org/10.5472/marumj.1244456

Cited By: 1

Abstract

Objective: Erectile dysfunction (ED) is a common condition in patients with heart failure (HF), which impairs quality of life. Our
study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin
receptor-neprilysin inhibitor (ARNI) treatment in addition to the current treatment, in terms of ED at the end of 6 months.
Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart
failure. The patients’ demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring
questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those
who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared.
Results: The median age of the patients was 53 (years). The median ejection fraction (EF) value was calculated to be 30% and no
significant difference was found between the groups (p: 0.122). It was found that N-terminal pro-brain natriuretic peptide (NT-pro-
BNP) levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those
who had not (respectively, 245 pg/ml, 200 pg/ml; p: 0.003). In the analysis performed to detect the presence of ED, it was discovered
that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment (p: 0.031) compared to
that in the group that had not (p: 0.031). When the ED sub-parameters were compared in terms of the 6-month change rate, it was
found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was
found in the other parameters (p: 0.001, p: 0.029).
Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of
life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for
6 months than in patients who had not.

Keywords

Erectile dysfunction, Heart failure, Angiotensin receptor-neprilysin inhibitor

References

• Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;29:117:25-146. doi: 10.1161/ CIRCULATIONAHA.107.187998
• Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13. doi: 10.1056/NEJM200.006.153422407.
• Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151:54-61. doi: 10.1016/s0022-5347(17)34871-1
• Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the “Cologne Male Survey.” Int J Impot Res 2000; 12:305- 11. doi: 10.1038/sj.ijir.3900622
• Schouten BWV, Bosch JLHR, Bernsen RMD, Blanker MH, Thomas S, Bohnen AM. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance, and duration of follow-up in the Krimpen Study. Int J Impot Res 2005; 17:58-62. doi: 10.1038/sj.ijir.3901264
• Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction, and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21. doi: 10.1016/j. amjcard.2005.12.018
• Rastogi S, Rodriguez J, Kapur V, Schwarz ER. Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int J Impot Res 2005;17 Suppl 1:25-36. doi: 10.1038/sj.ijir.3901426
• Bocchi E A, Guimarães G, Mocelin A, Bacal F, Bellotti G, Ramires J F. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103. doi: 10.1161/01. cir.000.002.7149. 83473.b6
• Schwarz ER, Kapur V, Bionat S, Rastogi S, Gupta R, Rosanio S. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int J Impot Res 2008;20:85-91. doi: 10.1038/sj.ijir.3901613
• Costa C, Virag R. The endothelial–erectile dysfunction connection: An essential update. J Sex Med 2009; 6 2390-404. doi: 10.1111/j.1743-6109.2009.01356.x
• Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007;61:2019-25. doi:10.1111/j.1742-1241.2007. 01629.x
• Anne I, Thorson MD. Sexual activity and the cardiac patient. Am J Geriatr Cardiol 2003;12 : 38-40. doi: 10.1111/j.1076- 7460.2003.01755.x.
• Karavitakis M, Komninos C, Theodorakis PN, et al. Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation. J Sex Med 2011;8:2405-14. doi: 10.1111/j.1743-6109.2011.02342. x.
• Gottlieb S, Khatta M, Friedmann E, et al. The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 2004;43:1542-9. doi :10.1016/j.jacc.2003.10.064
• Rosen, R.C., Riley, A., Wagner, G., Osterloh, I., Kirkpatrick, J., Mishra, A. (1997). The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30. doi: 10.1016/ s0090-4295(97)00238-0
• Ceyhun G, Erbay G. The relationship between ProNT BNP levels and erectiledysfunction in patients with chronic congestive heart failure. Ann Med Res 2021; 28: 652-6. doi:10.5455/annalsmedres.2020.06.676
• McMurray JJ, Packer M, Desai AS, et al . Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. doi: 10.1056/NEJMoa1409077
• Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensinconverting enzyme inhibition. Hypertension 2004;44:913-8. doi: 10.1161/01.HYP.000.014.6483.78994.56.
• Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2- terminal 20 peptide (PAMP). Br J Clin Pharmacol 2001; 52:159-64. doi: 10.1046/j.0306-5251.2001.1420. x.
• Marci C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol 2006; 103:149-56. doi: 10.1159/000092457
• Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol 2004; 99:76-82. doi: 10.1007/ s00395.004.0460-0.
• Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: Meta-analysis. J Am Heart Assoc 2019;8:012272. doi: 10.1161/JAHA.119.012272.
• Canale ML, Coviello K, Solarino G, et al. Case Series: Recovery of chemotherapy-related acute heart failure by the combined use of sacubitril valsartan and wearable cardioverter defibrillator: A novel winning combination in cardio-oncology. Front Cardiovasc Med 2022; 9:801143. doi: 10.3389/fcvm.2022.801143.
• Trivedi RK, Polhemus DJ, Li Z, et al. Combined angiotensin receptor-neprilysin inhibitors improve cardiac and vascular function via increased NO bioavailability in heart failure. J Am Heart Assoc 2018;7:008268. doi:10.1161/JAHA.117.008268
• Claudino M.A., Mora A, Janussi S, et al. Effect of Entresto (valsartan+sacubitril) in the cardiac function and contractile response of detrusor and corpus cavernosum smooth muscles of heart failure rats. FASEB Journal 2020; 34:1-1 doi:10.1096/ fasebj.2020.34.s1.07018
• Zhuang C, Guo Z, Wang W, Sun R, Qi M, Yu J. Sacubitril/ valsartan improves sexual function and fibrosis of the clitoral and vaginal tissues in female spontaneously hypertensive rats. J Cardiovasc Pharmacol 2022;79:858-72. doi: 10.1097/ FJC.000.000.0000001251.
• The PARADOR (Comparing ARNI With ACE Inhibitor on Endothelial Function) trial is a planned multisite, randomized, double-blind trial designed to compare the effects of sacubitril/ valsartan with enalapril on endothelial function in patients with HFrEF ClinicalTrials.gov Identifier: NCT03917459 Novartis. Comparing ARNI with ACE inhibitor on endothelial function (PARADOR), https://clinicaltrials.gov/ct2/show/ NCT03119623. NLM identifier: NCT03119623 (accessed December 2017 – completed August 2019)